D-0390-2025 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0390-2025 was initiated by Eugia US LLC on Apr 21, 2025 and is designated Class II. Reason for recall: Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances. The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
May 7, 2025
Initiation Date
Apr 21, 2025
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-430-01

Reason for recall

Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.

Distribution pattern

USA nationwide.

Code information

Lot# : 3TF24001, Exp 3/31/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0390-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0390-2025. Report a data issue: hello@regdatalab.com.